Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug
- 28 January 2020
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 34 (3) , 311-323
Abstract
ACT-709478 is a selective, orally available T-type calcium channel blocker being studied as a potential new treatment in epilepsy. ACT-709478 had previously been investigated in a single-ascending dose study up to a dose of 400 mg.Keywords
Funding Information
- Actelion Pharmaceuticals (AC-083-102)
- Idorsia Pharmaceuticals (AC-083-102)
This publication has 33 references indexed in Scilit:
- Drug-Resistant EpilepsyNew England Journal of Medicine, 2011
- Voltage-Gated Calcium ChannelsCold Spring Harbor Perspectives in Biology, 2011
- Pharmacokinetic–pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjectsBritish Journal of Clinical Pharmacology, 2011
- Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication responseEpilepsy & Behavior, 2010
- Role of voltage-gated calcium channels in epilepsyPflügers Archiv - European Journal of Physiology, 2009
- Voltage-Gated Calcium Channels and Idiopathic Generalized EpilepsiesPhysiological Reviews, 2006
- Epidemiology of Idiopathic Generalized EpilepsiesEpilepsia, 2005
- Biomarkers for the effects of antipsychotic drugs in healthy volunteersBritish Journal of Clinical Pharmacology, 2001
- Psychedelic Effects of Ketamine in Healthy VolunteersAnesthesiology, 1998
- Quantitative measurement of saccade amplitude, duration, and velocityNeurology, 1975